| Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 MC Sorbo, V Cento, VC Di Maio, AYM Howe, F Garcia, CF Perno, ... Drug Resistance Updates 37, 17-39, 2018 | 224 | 2018 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 102 | 2017 |
| Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses A Artese, V Svicher, G Costa, R Salpini, VC Di Maio, M Alkhatib, ... Drug Resistance Updates 53, 100721, 2020 | 101 | 2020 |
| Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B … VC Di Maio, V Cento, C Mirabelli, A Artese, G Costa, S Alcaro, CF Perno, ... Antimicrobial agents and chemotherapy 58 (5), 2781-2797, 2014 | 70 | 2014 |
| Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1–4 in Italy A Bertoli, MC Sorbo, M Aragri, I Lenci, E Teti, E Polilli, VC Di Maio, ... Scientific reports 8 (1), 8988, 2018 | 51 | 2018 |
| Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures JM Pawlotsky Seminars in Liver Disease 39 (03), 354-368, 2019 | 44 | 2019 |
| Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? VC Di Maio, V Cento, M Aragri, S Paolucci, T Pollicino, N Coppola, ... Journal of hepatology 68 (3), 597-600, 2018 | 38 | 2018 |
| Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals AYM Howe, C Rodrigo, EB Cunningham, MW Douglas, J Dietz, J Grebely, ... JHEP Reports 4 (5), 100462, 2022 | 36 | 2022 |
| Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen V Cento, F Van Hemert, M Neumann-Fraune, C Mirabelli, VC Di Maio, ... Journal of Infection 67 (4), 303-312, 2013 | 34 | 2013 |
| Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents FC Silberstein, VC Di Maio, M Aragri, M Ciotti, V Cento, CF Perno Hepatology 63 (3), 1058-1059, 2016 | 33 | 2016 |
| Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy J Dietz, VC Di Maio, A de Salazar, D Merino, J Vermehren, S Paolucci, ... Journal of Hepatology 74 (4), 801-810, 2021 | 31 | 2021 |
| Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy L Cuypers, B Vrancken, L Fabeni, N Marascio, V Cento, VC Di Maio, ... BMC Evolutionary Biology 17, 1-10, 2017 | 27 | 2017 |
| Viral resistance in HCV infection F Ceccherini-Silberstein, V Cento, VC Di Maio, CF Perno, A Craxì Current opinion in virology 32, 115-127, 2018 | 20 | 2018 |
| Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens V Cento, THT Nguyen, D Di Carlo, E Biliotti, L Gianserra, I Lenci, ... PLoS One 12 (5), e0177352, 2017 | 19 | 2017 |
| A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy V Cento, S Landonio, F De Luca, VCD Maio, V Micheli, C Mirabelli, ... Antiviral therapy 18 (4), 1-5, 2013 | 19 | 2013 |
| Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control R Salpini, M Alkhatib, G Costa, L Piermatteo, FA Ambrosio, VC Di Maio, ... Journal of Antimicrobial Chemotherapy 76 (2), 396-412, 2021 | 17 | 2021 |
| Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study V Cento, M Aragri, E Teti, E Polilli, A Bertoli, L Foroghi, S Barbaliscia, ... Journal of Antimicrobial Chemotherapy 72 (12), 3420-3424, 2017 | 17 | 2017 |
| Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district E Polilli, V Cento, U Restelli, F Ceccherini-Silberstein, M Aragri, ... ClinicoEconomics and Outcomes Research, 467-473, 2016 | 17 | 2016 |
| Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen A de Salazar, J Dietz, VC di Maio, J Vermehren, S Paolucci, B Müllhaupt, ... Journal of Antimicrobial Chemotherapy 75 (11), 3349-3358, 2020 | 16 | 2020 |
| Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C VC Di Maio, S Barbaliscia, E Teti, G Fiorentino, M Milana, S Paolucci, ... Liver International 41 (8), 1802-1814, 2021 | 15 | 2021 |
